Clinical Trial Update: Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial [Phase 3]

View source ↗

Summary

Phase 3 trial update for an EGFR antagonist chimeric anti-EGFR monoclonal antibody in metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Chimeric anti-EGFR monoclonal antibody

Snippet

Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: UNKNOWN